A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis

Stopped AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.

Conditions

• Rheumatoid Arthritis

Interventions

• DRUG: Fostamatinib

Sponsor

AstraZeneca